Submissions from 2022


(P44) Is Prophylactic Cranial Irradiation Necessary in Stage I-IIA Small Cell Lung Cancer Patients? A Single Institution Experience, Sondos Alkhatib, Aharon Feldman, Shirish M. Gadgeel, Andrew Popoff, Munther Ajlouni, Michael Simoff, and Benjamin Movsas


1544P Pre-treatment CT radiomics predicts survival in chemo-immunotherapy-treated small cell lung cancer, Joseph Bae, Prateek Prasanna, and Shirish M. Gadgeel


Association of immunotherapy and immunosuppression with severe COVID-19 disease in patients with cancer, Z. Bakouny, P. Grover, C. Labaki, J. Awosika, S. Gulati, C. Y. Hsu, M. A. Bilen, O. Eton, L. Fecher, Clara Hwang, H. Khan, R. R. McKay, E. Ruiz, L. Weissmann, M. A. Thompson, D. Shah, J. Warner, Y. Shyr, T. K. Choueiri, and T. Wise-Draper


KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRAS mutation, Tanios S. Bekaii-Saab, Alexander I. Spira, Rona Yaeger, Gary L. Buchschacher, Autumn Jackson McRee, Joshua K. Sabari, Melissa L. Johnson, Minal A. Barve, Navid Hafez, Karen Velastegui, James G. Christensen, Thian Kheoh, Hirak Der-Torossian, and Igor I. Rybkin


Clinical evaluation of NVL-520, a highly selective ROS1 inhibitor in patients with advanced ROS1-positive solid tumors: The phase I/II ARROS-1 study, B. Besse, M. Johnson, S. H. I. Ou, Shirish M. Gadgeel, A. Spira, J. Lin, E. Felip, A. J. van der Wekken, A. Calles, M. J. de Miguel, D. R. Camidge, Y. Elamin, G. D. L. Lopes, S. Liu, J. Bauman, D. Haggstrom, G. Riley, H. E. Pelish, V. W. Zhu, and A. Drilon


EP08.02-041 NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumors: The Phase 1/2 ARROS-1 Study, A. Drilon, S. H.I Ou, Shirish M. Gadgeel, M. Johnson, A. Spira, G. Lopes, B. Besse, E. Felip, A. J. van der Wekken, A. Calles, M. J. de Miguel, D. R. Camidge, Y. Elamin, S. Liu, J. Bauman, D. Haggstrom, G. Riley, H. E. Pelish, V. W. Zhu, and J. J. Lin


1549TiP DeLLphi-303: Phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE®), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC), Shirish M. Gadgeel, J. Al-Mondhiry, M. J. Ahn, S. W. Kim, L. Paz-Ares, H. Prenen, M. Boyer, J. G. Bustamanta Alvarez, B. Solomon, S. Huang, M. Minocha, M. Kistler, and N. Hashemi Sadraei


Relationship between RET fusion partner and treatment outcomes in patients (pts) with non-small cell lung cancer (NSCLC) from the phase I/II ARROW study and real-world data (RWD), Shirish M. Gadgeel, J. Gainor, F. Cappuzzo, E. Garralda, D. H. Lee, J. Mazieres, D. W. Kim, V. Zhu, G. Lopes, S. Miller, M. Nowicka, H. Trinh, S. M. Arndorfer, A. Rahman, J. Noe, Q. Zhang, and V. Subbiah


973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC, M. C. Garassino, Shirish M. Gadgeel, G. Speranza, E. Felip, E. Esteban Gonzalez, M. Domine Gomez, M. J. Hochmair, S. F. Powell, H. Bischoff, N. Peled, F. Grossi, R. Jennens, M. Reck, R. Hui, E. B. Garon, T. Kurata, J. E. Gray, P. O. Schwarzenberger, E. Jensen, and D. Rodriguez Abreu


A prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19, S. Halabi, B. Luo, H. Dzimitrowicz, Clara Hwang, T. M. Wise-Draper, C. Labaki, R. R. McKay, E. Ruiz, C. Rangel-Escareño, D. Farmakiotis, E. A. Griffiths, C. T. Jani, M. Accordino, C. Friese, E. Wulff-Burchfield, M. Puc, P. Yu, U. Topaloglu, S. Mishra, and J. Warner


790MO Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel), O. Hamid, Amy Weise, T. M. Kim, M. A. Mckean, N. J. Lakhani, J. Kaczmar, K. P. Papadopoulos, S. Chen, J. Mani, V. Jankovic, G. Kroog, T. Sims, I. Lowy, and G. Gullo


Phase 1 study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, plus cemiplimab in advanced melanoma, O. Hamid, Amy Weise, T. M. Kim, M. McKean, N. J. Lakhani, J. Kaczmar, K. P. Papadopoulos, S. Chen, J. Mani, V. Jankovic, G. Kroog, T. Sims, I. Lowy, and G. Gullo


OA06.06 Impact of Systemic Anti-cancer Treatments on Outcomes of COVID-19 in Patients with Thoracic Cancers: CCC19 Registry Analysis, a. Kulkarni, C. Hennessy, G. Wislon, V. Ramesh, Clara Hwang, A. Joy, Z. Bakouny, H. Khan, D. Vilar-Compte, R. McKay, C. Jani, J. W. Riess, M. Puc, A. Kasi, S. Berg, D. R. Castillo, B. Hayes-Lattin, W. Hosmer, D. Flora, S. Mishra, B. French, J. Warner, G. Lopes, S. Peters, and N. Duma


43P MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy, T. A. Leal, D. Berz, Igor I. Rybkin, W. T. Iams, D. Bruno, C. Blakely, A. Spira, M. Patel, D. M. Waterhouse, D. Richards, A. Pham, R. Jotte, E. B. Garon, D. S. Hong, R. Shazer, X. Yan, L. Latven, and K. He


The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial (SPRINT), N. Ohri, S. Jolly, B. T. Cooper, R. Kabarriti, W. R. Bodner III, J. Klein, S. Viswanathan, R. Kaufman, E. Shum, J. K. Sabari, H. Cheng, R. Gucalp, E. Castellucci, A. Qin, Shirish M. Gadgeel, and B. Halmos


Sentinel Lymph Node Positivity in Clinically Node Negative Breast Cancer Patients After Neoadjuvant Chemotherapy: Opportunities to Defer Intraoperative Frozen Section Analysis, Omar Qutob, Jessica Bensenhaver, Laura L. Susick, Lindsay Petersen, Anna Lehrberg, Fallon Dimaano, and Theresa Schwartz


Disparity Outcomes in Patients Undergoing Pancreas Surgery at an Urban Tertiary Care Center, Mariam A. Saad, Kendyll J. Gartrelle, Rupen Shah, Julie Clark, Kyra Langley, Erin Field, Christopher P. Steffes, and David S. Kwon


A single-center analysis of 30- and 90-day post-pancreatectomy complications in patients undergoing neoadjuvant radiation with EBRT versus MRI-guided SBRT, Mariam Saad, Julie Clark, Rupen A. Shah, Farzan Siddiqui, Parag J. Parikh, Kendyll J. Gartrelle, Abdul Kader Natour, Gazala Khan, and David Kwon


Update on a pilot study: Flumeltbi peripheral blood HLAhaploidentical stem cell transplantation with post-transplant cyclophosphamide and bortezomib (Cy2Bor3), Sowjanya Vuyyala, Edward Peres, Klodiana Neme, Nancy Mikulandric, Susan M. Wautelet, Danielle L. Pelland, Nada Zagar, Mary A. Trapp, Scott R. Rohrer, Elizabeth A. Henne, Sarah Szymanski, Josephine Emole, Muneer H. Abidi, and Shatha Farhan

Submissions from 2021


Satisfaction of hem/onc patients with video visits during the COVID-19 pandemic at a tertiary care center in Michigan, Fawzi Abu Rous, Pin Li, Mohamed Elgamal, Hussna Abunafessa, Rebecca Chacko, Sowjanya Vuyyala, Yaser Alkhatib, and Philip Kuriakose


O-15 Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in the overall population and Europe/North America subgroup, J Ajani, F El Hajbi, D Cunningham, M Alsina, P Thuss-Patience, G Scagliotti, M Van den Eynde, Igor Rybkin, L Shen, K Kato, S Kim, S D'Alonzo, W Yu, A Tao, and E Van Cutsem


1317P Renal toxicity in black patients with non-squamous non-small cell lung cancer treated with combination platinum-pemetrexed-pembrolizumab therapy, Nino Balanchivadze, Zeinab Nasser, Muhammad Shahid, Cortney McKay, Pin Li, Ryann Sohaney, and Shirish M. Gadgeel


P08.04 Comparative Clinical Outcomes Between EGFR Exon20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors, L Bazhenova, N Girard, A Minchom, S Ou, Shirish M. Gadgeel, J M. Trigo, S Viteri, A Londhe, P Mahadevia, and J Bauml


Molecular Biomarker Testing and Targeted Therapy Patterns in Patients with Acute Myelogenous Leukemia (AML) in Community Health Systems in the United States: A Real-World Data Analysis, Francesca Coutinho, Zartash Gul, Anna B. Berry, Michael A. Thompson, Christopher A. Willner, Sowjanya Vuyyala, Haley McCracken, Katherine Geverd, Jeanna Wallenta Law, Frank M. Wolf, Thomas D. Brown, and Philip Kuriakose


1281O Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C, R Dziadziuszko, S Peters, Shirish M. Gadgeel, S M. Shagan, E Felip, A Morabito, P Cheema, M C. Dols, Z Andric, C H. Barrios, M Yamaguchi, E Dansin, P Danchaivijitr, M Johnson, S Novello, D R. Gandara, E Schleifman, J Wang, and T S.K. Mok


1632P At home androgen deprivation therapy for patients with prostate cancer during the COVID-19 pandemic. One center experience, T Esakia, T Melkadze, K Tsiklauri, E Mariamidze, S Tsitsilashvili, N Otkhozoria, M Abuladze, N Jokhadze, and Nino Balanchivadze


P10.03 Pembrolizumab With or Without Chemotherapy for Advanced Lung Cancer: A Real-World Analysis of Key Prognostic Factors, Shirish M. Gadgeel, M Izano, C Sweetnam, Igor Rybkin, M Hendawi, J Weese, A Patel, D Reding, J Treisman, A Stafford, F Wolf, C Zhang, and T Brown

MO01.38 Registrational Dataset from the Phase 1/2 ARROW Trial of Pralsetinib (BLU-667) in Patients with Advanced RET Fusion+ Non-Small-Cell Lung Cancer (NSCLC), J F. Gainor, G Curigliano, D W. Kim, D H. Lee, B Besse, C S. Baik, R C. Doebele, P Cassier, G Lopes, D SW Tan, E Garralda, L Paz-Ares, B C. Cho, Shirish M. Gadgeel, M Thomas, S V. Liu, C Clifford, H Zhang, C D. Turner, and V Subbiah

MA04.07 Comparative Clinical Outcomes for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutations and Common EGFR Mutations, N Girard, L Bazhenova, A Minchom, S Ou, Shirish M. Gadgeel, J Trigo, S Viteri, G Li, P Mahadevia, A Londhe, D Backenroth, T Li, and J M. Bauml


61MO Biomarker analysis of men with enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) + enza in KEYNOTE-199, J N. Graff, S Tagawa, C Hoimes, W Gerritsen, U N. Vaishampayan, T Elliott, Clara Hwang, A J.T. Tije, A G. Omlin, R S. McDermott, R De Wit, P Qiu, C Poehlein, J Kim, L Suttner, R Cristescu, M J. Marton, C Schloss, J S. de Bono, and E S. Antonarakis


P10.04 Immunotherapy-Treated Non-Small Cell Lung Cancer Patients With Sensitizing Gene Alterations: A Real World Survival Analysis, Leila Khaddour, C Zhang, Faria Ali, Shirish M. Gadgeel, E Tadesse, M Thompson, D Reding, J Treisman, A Berry, M Izano, C Sweetnam, A Stafford, F Wolf, T Brown, and Igor Rybkin


A Phase 1 Dose Escalation Study of Dual PI3K and DNA PK Inhibitor, BR101801 in Adult Patients with Advanced Hematologic Malignancies, Tae Min Kim, Dok Hyun Yoon, Ahmad Mattour, Jorge M. Chaves, Emily Curran, Yoon Kyung Jeon, Bong-Seog Kim, and Seok Jin Kim


CT-423: Neuropsychiatric Disorders in Hospitalized Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma, O Lawal, O Lupak, I Udo, and Josephine Emole


1191O MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy, T A. Leal, D Berz, Igor I. Rybkin, W T. Iams, D Bruno, C Blakely, A Spira, M R. Patel, D M. Waterhouse, D Richards, A Pham, R Jotte, E B. Garon, D Hong, R Shazer, X Yan, L Latven, and K He


961MO Safety, efficacy, immunogenicity of arenavirus-based vectors HB-201 and HB-202 in patients with HPV16+ cancers, M R. Posner, A L. Ho, J Niu, L Nabell, R S. Leidner, J Nieva, D L. Richardson, A T. Pearson, Ding Wang, K Chung, D R. Adkins, A Pimentel, S Wong, C Lacobucci, X Qing, K Katchar, K Schlienger, I Matushansky, S Fu, and D G. Pfister

KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non-small cell lung cancer (NSCLC) harboring KRASG12C mutation, G J. Riely, S H.I. Ou, Igor Rybkin, A Spira, K Papadopoulos, J K. Sabari, M Johnson, R S. Heist, L Bazhenova, M Barve, J M. Pacheco, K Velastegui, C Cilliers, P Olson, J G. Christensen, T Kheoh, R C. Chao, and P A. Janne


Preliminary results from a phase I/II study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors, M R. Sharma, R D. Carvajal, G J. Hanna, Y K. Kang, J Lee, K W. Lee, B T. Li, K N. Moore, M Pegram, D Rasco, A Spira, Ding Wang, B A. Weinberg, M Alonso, L Fang, A Husain, M Kowanetz, E A. Perez, and E I. Dumbrava


OA17.04 The Global Impact of COVID-19 on Telehealth and Care for Persons With Thoracic Cancers, M Smeltzer, B Bunn, Y S. Choi, L Coate, J Corona-Cruz, A Drilon, N Duma, M Edelman, M J. Fidler, Shirish M. Gadgeel, Y Goto, R Herbst, M Hesdorffer, K Higgins, B Labdi, T Leal, S Liu, J Mazotti, S Novello, S Patel, S Popat, R Ramirez, K Reckamp, N Reguart, R Soo, A Tan, J Wolf, S Yano, B Stiles, and A Baird

P77.04 PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors, D R. Spigel, D Rodríguez-Abreu, F Cappuzzo, V Velcheti, A K. Ganti, D Johnson, R Govindan, S Antonia, B Besse, M Altan, M Edelman, S Ramalingam, E Felip, Shirish M. Gadgeel, O Juan-Vidal, A Gupta, S Currie, W Lin, M Tagliaferri, and M Reck

MO01.33 CRESTONE – Clinical Study of REsponse to Seribantumab in Tumors with NEuregulin-1 (NRG1) Fusions – A Phase 2 Study of the anti-HER3 mAb for Advanced or Metastatic Solid Tumors (NCT04383210), D Spigel, S N. Waqar, M E. Burkard, J J. Lin, Y K. Chae, M A. Socinski, Shirish M. Gadgeel, K L. Reckamp, S M. Leland, D Plessinger, L Kunkel, J R. Bauman, G Otterson, B Halmos, Ou SH Ignatius, T Patil, Y Y. Elamin, and E S. Kim


Hyperhemolysis Syndrome in SCD Patient: Reminder of a Rare but Life-Threatening Complication of Blood Transfusion, Aroob Sweidan, Sowjanya Vuyyala, Peter Xie, Mohammad Alhyari, Vrushali Dabak, and Zaher K. Otrock


LUMINOS-102: PVSRIPO with or without immune checkpoint blockade in unresectable anti-PD-1 refractory melanoma, Ding Wang, C. Lance Cowey, Evan Pisick, John Kirkwood, Daniel Corum, Shannon R. Morris, Andrea T. Kelly, Jessica Sorrentino, Lori Mixson, Adam Dickinson, W. Garrett Nichols, and Yana G. Najjar

P78.05 Patterns of irAE During First Line Pembrolizumab for NSCLC: Incidence, Risk Factors, and Impact on Clinical Outcome, C Wood, G Lopez, L Zhao, M Li, N Surya, S Patel, M Grogan, E Bertino, P Shields, K He, D Carbone, G Otterson, C Presley, B Pannecouk, G Kalemkerian, B Schneider, Shirish M. Gadgeel, N Ramnath, D Owen, and A Qin

Submissions from 2020

A multicenter, open-label, dose-escalation, first-in-man study of MetAP2 inhibitor M8891 in patients with advanced solid tumours, M A. Carducci, Ding Wang, C Habermehl, M Bödding, F Rohdich, S Stinchi, O Karpenko, C Gimmi, and P LoRusso

Towards Evidence Based Practice: The American Radium Society (ARS) and American College of Radiology (ACR) Appropriate Use Guidelines on Radiation Therapy for Muscle-Invasive Bladder Cancer, T K. Dinh, T Mitin, K Hoffman, Clara Hwang, R J. Karnes, A Kishan, S Liauw, S Lloyd, L Potters, T Showalter, A Taira, N Vapiwala, N Zaorsky, A D'Amico, P Nguyen, and B Davis

Blood-based genomic profiling of advanced non-small cell lung cancer (aNSCLC) patients (pts) from blood first assay screening trial (BFAST) and comparison with real-world data (RWD), R Dziadziuszko, Q Zhang, X Li, S M. Paul, M Sugidono, S Mocci, A Kinkolykh, D S. Shames, V Archer, M S. Mathisen, D X. Jin, Shirish M. Gadgeel, S Peters, and T Mok

Prospective Randomized Study of Prophylactic Ciprofloxacin Versus Levofloxacin in Hematopoietic Stem Cell Transplant Patients: An Interim Report, Shatha Farhan, Georgiana Marusca, Michael Bazydlo, Klodiana Neme, Nancy Mikulandric, Josena K. Stephen, Nada Kortam, R Mayur, Danielle L. Pelland, Nada Zagar, Mary A. Trapp, Elizabeth A. Henne, Scott R. Rohrer, Sarah Szymanski, Josephine Emole, Edward Peres, and Nalini Janakiraman

Blood first assay screening trial (BFAST) in patients (pts) with 1L NSCLC: ALK+ cohort updated biomarker analyses, Shirish M. Gadgeel, M Yan, S M. Paul, M Mathisen, S Mocci, Z J. Assaf, R Patel, E S. Sokol, T Mok, S Peters, L Paz-Ares, and R Dziadziuszko

Racial Disparities Among Pancreatic Adenocarcinoma Patients: A Retrospective Survival Analysis of Non-Metastatic Pancreatic Cancer Patients, Kendyll J. Gartrelle, Eric M. Schaff, Celina Kirsch, David Kwon, Munther Ajlouni, Gazala Khan, Rupen Shah, Irina Dobrosotskaya, Parag J. Parikh, and Farzan Siddiqui

Does Age Impact Outcomes of Oropharyngeal squamous cell carcinoma?, Ahmed I. Ghanem, Matthew Schymick, Souheyla Bachiri, Remonda M. Khalil, Charlotte Burmeister, Jawad Sheqwara, Steven S. Chang, Tamer Ghanem, and Farzan Siddiqui

Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-199 cohorts 4-5, J N. Graff, E S. Antonarakis, C J. Hoimes, S T. Tagawa, Clara Hwang, D Kilari, A J. Ten Tije, A G. Omlin, R S. McDermott, U N. Vaishampayan, A Elliott, H Wu, J Kim, C Schloss, and J S. De Bono

Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate, E P. Hamilton, M A. Barve, A W. Tolcher, J Buscema, K P. Papadopoulos, C Zarwan, C K. Anderson, D Doroshow, Ding Wang, D Huebner, V M. Jansen, D Jarlenski, R Mosher, J Kaufman, K N. Moore, and D L. Richardson


American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC, Kristin A. Higgins, Charles B. Simone, Arya Amini, Indrin J. Chetty, Jessica Donington, Martin J. Edelman, Stephen G. Chun, Larry L. Kestin, Benjamin Movsas, George B. Rodrigues, Kenneth E. Rosenzweig, Ben J. Slotman, Igor Rybkin, Andrea Wolf, and Joe Y. Chang

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation, P A. Jänne, Igor I. Rybkin, A I. Spira, G J. Riely, K P. Papadopoulos, J K. Sabari, M L. Johnson, R S. Heist, L Bazhenova, M Barve, J M. Pacheco, T A. Leal, K Velastegui, C Cornelius, P Olson, J G. Christensen, T Kheoh, R C. Chao, and S H.I. Ou


KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation, Melissa L. Johnson, Sai-Hong Ignatius Ou, Minal Barve, Igor I. Rybkin, Kyriakos P. Papadopoulos, Ticiana A. Leal, Karen Velastegui, James G. Christensen, Thian Kheoh, Richard C. Chao, and Jared Weiss

Clinical outcomes of patient migration in locally advanced rectal cancer from community cancer centers: An analysis of the National Cancer Database, R Kumar, S Bhandari, P Ngo, Sukhpreet RK Singh, S J. Malapati, and A Rojan

Progressive hyperleukocytosis associates with differential syndrome in acute promyelocytic leukemia patients treated with all-trans retinoic acid and arsenic trioxide, Qunfang Li and Yue Guo

4-year survival in randomised phase II (POPLAR) and phase III (OAK) studies of atezolizumab (atezo) vs docetaxel (doc) in pre-treated NSCLC, J Mazieres, A Rittmeyer, Shirish M. Gadgeel, T Hida, D Gandara, D Cortinovis, F Barlesi, W Yu, C Matheny, M Ballinger, and K Park

KEYNOTE-199 cohorts 4 and 5: Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC), R McDermott, J N. Graff, E S. Antonarakis, C J. Hoimes, S T. Tagawa, Clara Hwang, D Kilari, A JT Tije, A Omlin, U N. Vaishampayan, A Elliott, H Wu, J Kim, C Schloss, and J S. De Bono

Phase Ib/II study of ibrutinib (ibr) in combination with cetuximab (cetux) in patients (pts) with previously treated metastatic colorectal cancer (mCRC), D Y. Oh, T Arkenau, K W. Lee, M Alsina, F M. Marti, I J. Chung, W Saif, Ding Wang, P O'Dwyer, I Chau, M A. Lee, E Chong, J Hilger-Rolfe, G Cole, and S Y. Kim

KEYNOTE-199 phase II study of pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update, A G. Omlin, J N. Graff, C J. Hoimes, S T. Tagawa, Clara Hwang, D Kilari, A J. Ten Tije, R McDermott, U N. Vaishampayan, T Elliott, W R. Gerritsen, H Wu, J Kim, C Schloss, J S. de Bono, and E S. Antonarakis

Lorlatinib in patients with ALK+ NSCLC treated beyond initial disease progression, S I. Ou, B Solomon, A Shaw, Shirish M. Gadgeel, B Besse, R A. Soo, A Abbattista, H Thurm, F Toffalorio, R J. Wiltshire, and A Bearz

Tissue sound speed is more strongly associated with breast cancer risk than mammographic percent density: A comparative case-control study, M Sak, N Duric, R Pfeiffer, M Sherman, P Littrup, M Simon, D Gorski, T Albrecht, Haythem Y. Ali, R Brem, S Fan, and G Gierach

Magnetic Resonance Guided Stereotactic Ablative Radiation Therapy Versus External Beam RT with Chemotherapy For Pancreatic Cancer: Single Institution Toxicity Analysis Of Patients Treated In An Urban Academic Center, Eric Schaff, Kendyll J. Gartrelle, Celina Kirsch, Farzan Siddiqui, Munther Ajlouni, Jadranka Dragovic, Ibrahim Aref, Mira M. Shah, David Kwon, Irina Dobrosotskaya, Rupen Shah, Gazala Khan, and Parag J. Parikh

A Phase 1b/2a Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Nanogenistein in Combination with Chemoradiotherapy for Non-small Cell Lung Cancer, C B. Simone, Benjamin Movsas, E M. Gore, P Mohindra, Z Vujaskovic, Ding Wang, Munther Ajlouni, S Menon, J Thompson, Stephen L. Brown, M Kurman, J C. Dykstra, L Rillo, M Ingram, A Serebrenik, and M D. Kaytor

Initial results of a phase I study of MK-4830, a first-in-class anti–immunoglobulin-like transcript 4 (ILT4) myeloid-specific antibody in patients (pts) with advanced solid tumours, L L. Siu, Ding Wang, J Hilton, R Geva, D Rasco, A K. Abraham, J F. Markensohn, L Suttner, S Siddiqi, R A. Altura, and C Maurice-Dror

Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199, U N. Vaishampayan, T Elliott, A G. Omlin, J N. Graff, C J. Hoimes, S T. Tagawa, Clara Hwang, D Kilari, A JT Tije, R S. McDermott, W R. Gerritsen, H Wu, J Kim, S Schloss, J S. de Bono, and E S. Antonarakis

Submissions from 2019

A differential response to cetuximab in patients with recurrent unresectable or metastatic head and neck cancer following immunotherapy (IO) exposure: An institutional experience, Haythem Ali, Z A. Rahman, and Jawad Sheqwara

Evaluation of Tumor Heterogeneity in Prostate Biopsy Samples, P D. Arachchige, Shannon Carskadon, G Dhamdhere, Mireya Diaz-Insua, R Craig, James O. Peabody, Madhu P. Menon, Sean R. Williamson, Nilesh S. Gupta, and Nallasivam Palanisamy

Four vs six cycles of docetaxel and cyclophosphamide (TC) in early stage triple-negative breast cancer, Aparna Basu, Hadi Mohammed, Sharmeen Mahmood, Vrushali Dabak, and Randa Loutfi

Phase I and expansion cohort study of adjuvant cisplatin, intensity-modulated radiation therapy (IMRT), and MK-3475 (Pembrolizumab) in high-risk head and neck squamous cell carcinoma (HNSCC), J E. Bauman, J Harris, R Uppaluri, M Yao, R L. Ferris, J Chen, R C. Jordan, N P. Joshi, S Jujjuvaparu, D Blakaj, M Razaq, Jawad Sheqwara, L K. Mell, N Sen, D A. Clump, M Garg, E Yilmaz, and Q T. Le

Antitumor Activity of Pembrolizumab Plus Dinaciclib in Patients with Diffuse Large B Cell Lymphoma: The Phase 1b KEYNOTE-155 Study, G Gregory, P Walker, D Mahadevan, Ding Wang, J Chang, F Hernandez-Ilizaliturri, A Klein, W Rybka, N Wagner-Johnson, C Escobar, J M. Pagel, A Mohrbacher, S Opat, J Shortt, H Ma, J Gwo, M Farooqui, and H Quach

Breakthrough hemolysis in adult patients with paroxysmal nocturnal hemoglobinuria treated with Ravulizumab: Results of a 52-week extension from two phase 3 studies, Anita Hill, Caroline I. Piatek, Régis Peffault de Latour, Lily L.L. Wong, Richard A. Wells, Robert A. Brodsky, Jin Seok Kim, Junichi Nishimura, Philip Kuriakose, Rodrigo Pavani, Peng Liu, Stephan Ortiz, Hubert Schrezenmeier, Jong-Wook Lee, and Austin Kulasekararaj

Phase II multicenter study of antroquinonol in patients with stage IV non-small cell lung cancer who have failed at least two lines of anti-cancer therapy, C L. Ho, D S. Ettinger, P N. Chen, H Cheng, W C. Wen, S Y. Wu, T M. Jahan, M J. Fidler, B W. Lash, Igor I. Rybkin, and N Stanton

Tumors expressing ACKR1 exhibit a unique signature of tumor-infiltrating immune cells in women with breast cancer., B D. Jenkins, T Fleifel, R Martini, H Ali, Lisa A. Newman, and M Davis

Predictive accuracy of the low erythropoietin level for the diagnosis of polycythemia vera, Oleksandra Lupak, Xiaoxia Han, Peter Xie, Sharmeen Mahmood, Hadi Mohammed, and Vijayalakshmi Donthireddy

Arctin and Arctigenin as a Potential Treatment for Solid Tumors, Mani Maheshwari, Joe Media, Q Jia, and Frederick A. Valeriote

Outcomes of tbo-filgrastim, filgrastim-sndz or filgrastim for mobilization in patients undergoing an autologous hematopoietic stem cell transplant: A single center experience, Klodiana Neme, David R. Henkin, Nancy Mikulandric, Meredith Grycki, Alexander Michaels, Chadd Smith, and Josephine Emole

First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies, K P. Papadopoulos, N J. Lakhani, M L. Johnson, H Park, Ding Wang, T A. Yap, A Dowlati, R G. Maki, F Lynce, S V. Ulahannan, K Kelly, T N. Sims, A L. Bredlau, D Bramble, A G. Ortiz, M Zhu, H Chen, M Karasarides, and G Kroog

A study of REGN3767, an antiLAG3 antibody, alone and in combination with cemiplimab (REGN2810), an antiPD1 antibody in advanced cancers, K P. Papadopoulos, N Lakhani, M L. Johnson, H Park, Ding Wang, T A. Yap, K N. Moore, T N. Sims, C A. Emeremni, M Karasarides, and G S. Kroog

Patient preferences for the treatment of paroxysmal nocturnal hemoglobinuria: Interim results of a patient survey of ravulizumab (ALXN1210) and eculizumab, J Peipert, A Kulasekararaj, F Gonzalez-Fernandez, S Yount, C Martens, A Sparling, K Webster, D Cella, S Rottinghaus, B Donato, I Tomazos, A Gaya Valls, L Mitchell, A Hill, R Wells, C Piatek, Philip Kuriakose, I Murakhovskaya, S Khaled, and K Kaiser

2629 IV Iron in the Setting of Value-Based Care: Quality-of-Life Improvement and Perioperative Optimization of Anemia in The Gynecologic Population, Haleema Saeed, Sharmeen Mahmood, M R. Girgis, Ghadear Shukr, Philip Kuriakose, and Roopina Sangha

Fully integrated multi-disciplinary care in head and neck cancer: The Henry Ford Health System model, Amy M. Williams

Submissions from 2018

Utilization of the three Magee equations to select patients for genomic testing., Haythem Y. Ali, Z Abdel-Rahman, Laura Favazza, and Dhananjay A. Chitale

Evaluation of ERG as a biomarker of responsiveness in a randomized trial of enzalutamide in combination with androgen deprivation in metastatic hormone sensitive prostate cancer., S R. Chinni, U N. Vaishampayan, L K. Heilbrun, L Semaan, D Smith, D Modi, P Monk, Sheela Tejwani, G Sonpavde, K Dobson, B Dickow, E Heath, J Fontana, and M L. Cher

Preparation and cytotoxicity evaluation of acetylated fijianolides (A.K.A. laulimalide)., C V. Cook, T A. Johnson, D Coppage, N L. McIntosh, M A. Ogarrio, K Tenney, Frederick A. Valeriote, and P Crews

Neoadjuvant phase II trial of chemo-radiotherapy (CRT) in patients with resectable (R) and borderline resectable (BR) pancreatic ductal adenocarcinoma (PDA)., V Damarla, Irina Dobrosotskaya, Farzan Siddiqui, Ira Wollner, Mohammad Raoufi, Jia Li, David Kwon, and Gazala Khan

Outcome of non-germinal center/activated b-cell type diffuse large b-cell lymphoma determined by ihc in a single institution over 7 years., M R. Girgis, Shatha Farhan, Nalini Janakiraman, and Edward Peres

Phase Ib study of anetumab ravtansine in combination with pemetrexed and cisplatin in patients with mesothelin-expressing epithelial mesothelioma or nonsquamous non-small cell lung cancer., R Hassan, Ding Wang, J Wrangle, A Thomas, A Byars, L Asschert, R Atienza, P Rajagopalan, A Walter, J Zhang, N Sarapa, and H Kindler

Lenalidomide maintenance therapy after autologous peripheral blood stem cell transplant (pbsct) in multiple myeloma patients: Factors that impact treatment., Pushpinderdeep Kahlon, N K. Sandhu, Philip Kuriakose, and Edward Peres

Horsies and bunnies: A comparison of antithymocyte globulin in allogeneic stem cell transplant., C Lu, Klodiana Neme, Nancy Mikulandric, Meredith Grycki, D Pelland, Shatha Farhan, Nalini Janakiraman, Edward Peres, V Vogel, and E Szandzik

Primary versus secondary autoimmune hemolytic anemia: A retrospective analysis of diagnostic patterns and treatment outcomes, Laurel Mueller, Hussna Abunafessa, Diego Cabrera-Fernandez, and Philip Kuriakose

Busulfan pharmacokinetics and cd4 reconstitution after stem cell transplant in patients with myeloid neoplasms., Neha Patil, Michael Bazydlo, Edward Peres, Nalini Janakiraman, and Shatha Farhan

Dynamic pro-survival signaling mediates resistance to androgen receptor targeted therapy in ARv7 splice variant expressing prostate cancer models., Amanda B. Pilling and Clara Hwang

Chronic Kidney Disease (CKD) in the U.S. Hemophilia Population: A Cohort Study, Suman L. Sood, Dunlei Cheng, Amy Shapiro, Craig M. Kessler, Nigel S. Key, Doris Quon, M. Elaine Eyster, Marilyn J. Manco-Johnson, Christine L. Kempton, Adam Cuker, Margaret V. Ragni, Philip Kuriakose, Annette von Drygalski, Peter A. Kouides, Miguel A. Escobar, Allison P. Wheeler, Tzu-Fei Weng, Cindy A. Leissinger, Sarah Galdzicka, and Barbara A. Konkle

A case of thrombotic thrombocytopenic purpura and pancreatitis as a result of milk-alkali syndrome., B Souther, A Patel, and L Sutkowi-Toomajian

A case of thrombotic thrombocytopenic purpura and pancreatitis as a result of milk-alkali syndrome, B. Souther, A. Patel, and Lynette Sutkowi-Toomajian

Institutional adherence to National Comprehensive Cancer Network (NCCN) guidelines in neoadjuvant treatment of breast cancer and its correlation to outcomes., R K. Vaddepally, A Hejab, and Haythem Y. Ali

Randomized trial of enzalutamide versus bicalutamide in combination with androgen deprivation in metastatic hormone sensitive prostate cancer: A Prostate Cancer Clinical Trials Consortium trial., U N. Vaishampayan, L K. Heilbrun, P Monk, Sheela Tejwani, G Sonpavde, D Smith, P Jasti, K Dobson, E I. Heath, M L. Cher, S Chinni, and J A. Fontana

Enhancing psychosocial screening, surveillance, and management of Oncology Care Model patients under treatment with palliative intent, T Varkas, Michael Ryan, D Harrison, Daniel J. Miller, A Williams, and W Goldberg